NASDAQ:AMLX | Cash Flow Statement | Amylyx Pharmaceuticals, Inc.

Complete source-backed cash-flow history.

Available history
2021-03-31 to 2026-06-30
Data captured

Historical Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2026-06-30-$43.42M
2026-03-31-$41.28M-$36.88M$36.26M$3.22M
2025-12-31-$33M-$27.9M$86,000.00$29.47M-$208,000.00
2025-09-30-$34.39M
2025-06-30-$41.44M
2025-03-31-$35.91M-$39.82M$11,000.00-$43.66M$65.66M
2024-12-31-$37.55M-$59.01M$20,000.00$64.98M$110,000.00
2024-09-30-$72.7M
2024-06-30-$72.7M
2024-03-31-$118.79M-$489,000.00$67,000.00$819,000.00$131,000.00
2023-12-31$4.73M$13.55M$356,000.00$20.93M$230,000.00
2023-09-30$20.89M
2023-06-30$22.07M
2023-03-31$1.57M-$5.07M$250,000.00$55.99M$1.04M
2022-12-31-$42.7M-$49.7M$620,000.00-$228.18M$232.16M
2022-09-30-$53.76M
2022-06-30-$54.07M
2022-03-31-$47.85M-$40.63M$342,000.00-$99.31M$200.46M
2021-12-31-$28.34M-$28.24M$186,000.00$2.81M-$1.07M
2021-09-30-$23.14M
2021-06-30-$21.92M
2021-03-31-$14.52M-$12.64M$14,000.00-$14,000.00$25.93M

Annual Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2025-12-31-$144.74M-$123.34M$138,000.00$14.04M$257.03M
2024-12-31-$301.74M-$167.65M$157,000.00$75.65M$348,000.00
2023-12-31$49.27M$11.92M$1.24M$92.05M$3.54M
2022-12-31-$198.38M-$179.87M$2.53M-$238.99M$431.79M
2021-12-31-$87.93M-$74.8M$353,000.00-$46.41M$158.51M